Salesforce Ventures will invest another $250m as the data management software provider floated above its range at a valuation just short of $29bn.

Lennar, SoftBank, Access Industries and Alphabet are set to score exits from the real estate transaction manager, valued at $4.8bn in the deal.

Baxter International scored an exit as dialysis machine developer Outset Medical floated above its range in an upsized offering.

Small molecule drug developer C4 has fied for a $100m initial public offering, three months after the Dana-Farber Cancer Institute spinout raised a $170m round.

Exosome therapy developer Codiak Biosciences – based on research at Gothenburg and MD Anderson Cancer Center – has filed to raise up to $100m.

PMV Pharmaceuticals – built on foundational work at Princeton – will use some of the proceeds to complete phase 1 trials of its lead asset.

QuantaMatrix is targeting $17.80 to $22.30 per share under a regulation permitting a listing on the basis of growth and technology potential.

UT Southwestern-linked CNS disease drug developer Taysha has filed to raise up to $100m in an IPO, just weeks after its $96m series B.

Stanford spinout QuantumScape is set to merge with NYSE-listed Kensington Capital Acquisition in a $700m deal that will value the combined company at $3.3bn.

The laser manufacturing equipment maker is going public on Shanghai's Star Market two years after a Legend Capital-backed seed round.